Information Provided By:
Fly News Breaks for August 11, 2015
PBYI
Aug 11, 2015 | 07:33 EDT
After surveying oncologists, RBC Capital says the results indicate that oncologists are prepared to use the company's neratinib drug in the majority of HER2+ patients in the extended adjuvant setting, The firm keeps an Outperform rating on Puma.
News For PBYI From the Last 2 Days
There are no results for your query PBYI